Olanzapine

Generic Name: Olanzapine

Brand Names: Lybalvi, Olazax, Symbyax, Zalasta, Zypadhera, Zyprexa, Olanzapine Glenmark Europe, Olanzapine Apotex, Olanzapine Teva, Olazax Disperzi, Olanzapine Mylan, Zyprexa Velotab, Olanzapine Glenmark

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₂₀N_₄S

CAS Number: 132539-06-1

Unique Ingredient Identifier: N7U69T4SZR

Background: Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles clozapine and only differs by two additional methyl groups and the absence of a chloride moiety. It was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996.

Indication: Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.

Olanzapine is also indicated, in combination with lithium or valproate for the short-term treatment of acute manic or mixed episodes associated with bipolar I disorder in adults.

As well, olanzapine is indicated, in combination with fluoxetine for the treatment of episodes of depression associated with bipolar disorder type 1 and treatment-resistant depression in patients over 10 years old.

Olanzapine is also approved for the management of psychomotor agitation associated with schizophrenia and bipolar I mania.

Schizophrenia is a complex biochemical brain disorder that affects the person's ability to differentiate reality. It is usually observed as the presence of delusions, hallucinations, social withdrawal and disturbed thinking.

Bipolar disorder is a mental health condition defined by periods of extreme mood disturbances. It is categorized in different types from which type 1 is known to involve episodes of severe mania and often depression while type 2 presents less severe forms of mania.

Olanzapine is also indicated in combination with samidorphan for the treatment of bipolar I disorder, either as an adjunct to lithium or valproate or as monotherapy for the acute treatment of manic or mixed episodes or as maintenance therapy, and for the treatment of schizophrenia in adults.

Associated Conditions: Acute Agitation, Bipolar 1 Disorder, Bipolar Disorder With Manic or Mixed Episodes, Delirium, Delusional Parasitosis, Depressive Episodes, Gilles de la Tourette's Syndrome, Major depressive disorder, recurrent episode, Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode

Clinical Trials

Olanzapine in the Treatment of Hair Pulling (Trichotillomania)

Phase 4

Completed

Conditions: Trichotillomania

First Posted Date: 2005-09-16

Last Posted Date: 2006-09-11

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 34

Registration Number: NCT00182507

Locations: 🇨🇦
Hamilton Health Sciences, McMaster University Medical Centre, Hamilton, Ontario, Canada

Long-Term Olanzapine Treatment in Children With Autism

Phase 2

Completed

Conditions: Autism

Interventions: Drug: Olanzapine

First Posted Date: 2005-09-16

Last Posted Date: 2014-08-15

Lead Sponsor: Drexel University

Target Recruit Count: 32

Registration Number: NCT00183404

Locations: 🇺🇸
Drexel University College of Medicine at Friends Hospital, Philadelphia, Pennsylvania, United States

6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: asenapine
Drug: olanzapine

First Posted Date: 2005-09-15

Last Posted Date: 2022-02-09

Lead Sponsor: Organon and Co

Target Recruit Count: 196

Registration Number: NCT00174265

Olanzapine Versus Clozapine in Treatment Refractory Schizophrenia

Not Applicable

Completed

Conditions: Schizoaffective Disorder
Schizophrenia

First Posted Date: 2005-09-15

Last Posted Date: 2005-09-15

Lead Sponsor: Vanderbilt University

Target Recruit Count: 80

Registration Number: NCT00179231

Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar Disorder

Not Applicable

Completed

Conditions: Schizophrenia
Schizoaffective Disorder
Depressive Disorder, Major
Bipolar Disorder

Interventions: Drug: olanzapine versus risperidone

First Posted Date: 2005-09-15

Last Posted Date: 2008-08-26

Lead Sponsor: Vanderbilt University

Target Recruit Count: 300

Registration Number: NCT00179062

Locations: 🇺🇸
Psychiatric Hospital at Vanderbilt, Nashville, Tennessee, United States

Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study

Phase 4

Completed

Conditions: Bipolar Disorder

First Posted Date: 2005-09-15

Last Posted Date: 2005-09-15

Lead Sponsor: University of Pittsburgh

Target Recruit Count: 60

Registration Number: NCT00177567

Locations: 🇺🇸
University of Pittsubrgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States